536 related articles for article (PubMed ID: 15653751)
1. Down-regulation of normal human T cell blast activation: roles of APO2L/TRAIL, FasL, and c- FLIP, Bim, or Bcl-x isoform expression.
Bosque A; Pardo J; Martínez-Lorenzo MJ; Iturralde M; Marzo I; Piñeiro A; Alava MA; Naval J; Anel A
J Leukoc Biol; 2005 Apr; 77(4):568-78. PubMed ID: 15653751
[TBL] [Abstract][Full Text] [Related]
2. Human CD8+ T cell blasts are more sensitive than CD4+ T cell blasts to regulation by APO2L/TRAIL.
Bosque A; Pardo J; Martínez-Lorenzo MJ; Lasierra P; Larrad L; Marzo I; Naval J; Anel A
Eur J Immunol; 2005 Jun; 35(6):1812-21. PubMed ID: 15884050
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
4. Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells.
Monleón I; Martínez-Lorenzo MJ; Monteagudo L; Lasierra P; Taulés M; Iturralde M; Piñeiro A; Larrad L; Alava MA; Naval J; Anel A
J Immunol; 2001 Dec; 167(12):6736-44. PubMed ID: 11739488
[TBL] [Abstract][Full Text] [Related]
5. CD59 cross-linking induces secretion of APO2 ligand in overactivated human T cells.
Monleón I; Martínez-Lorenzo MJ; Anel A; Lasierra P; Larrad L; Piñeiro A; Naval J; Alava MA
Eur J Immunol; 2000 Apr; 30(4):1078-87. PubMed ID: 10760796
[TBL] [Abstract][Full Text] [Related]
6. Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering.
Sandalova E; Wei CH; Masucci MG; Levitsky V
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3011-6. PubMed ID: 14970329
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis by IL-2 deprivation in human CD8+ T cell blasts predominates over death receptor ligation, requires Bim expression and is associated with Mcl-1 loss.
Bosque A; Marzo I; Naval J; Anel A
Mol Immunol; 2007 Feb; 44(6):1446-53. PubMed ID: 16806475
[TBL] [Abstract][Full Text] [Related]
8. Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway.
Siegmund D; Mauri D; Peters N; Juo P; Thome M; Reichwein M; Blenis J; Scheurich P; Tschopp J; Wajant H
J Biol Chem; 2001 Aug; 276(35):32585-90. PubMed ID: 11384965
[TBL] [Abstract][Full Text] [Related]
9. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells.
Martínez-Lorenzo MJ; Alava MA; Gamen S; Kim KJ; Chuntharapai A; Piñeiro A; Naval J; Anel A
Eur J Immunol; 1998 Sep; 28(9):2714-25. PubMed ID: 9754559
[TBL] [Abstract][Full Text] [Related]
10. Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death.
Boussiotis VA; Lee BJ; Freeman GJ; Gribben JG; Nadler LM
J Immunol; 1997 Oct; 159(7):3156-67. PubMed ID: 9317113
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis signaling pathways in normal T cells: differential activity of Bcl-2 and IL-1beta-converting enzyme family protease inhibitors on glucocorticoid- and Fas-mediated cytotoxicity.
Moreno MB; Memon SA; Zacharchuk CM
J Immunol; 1996 Nov; 157(9):3845-9. PubMed ID: 8892614
[TBL] [Abstract][Full Text] [Related]
12. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention.
Ahmad M; Shi Y
Oncogene; 2000 Jul; 19(30):3363-71. PubMed ID: 10918593
[TBL] [Abstract][Full Text] [Related]
13. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.
Fulda S; Meyer E; Debatin KM
Cancer Res; 2000 Jul; 60(14):3947-56. PubMed ID: 10919673
[TBL] [Abstract][Full Text] [Related]
14. A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells.
Petak I; Vernes R; Szucs KS; Anozie M; Izeradjene K; Douglas L; Tillman DM; Phillips DC; Houghton JA
Cell Death Differ; 2003 Jun; 10(6):729-39. PubMed ID: 12761581
[TBL] [Abstract][Full Text] [Related]
15. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
Poulaki V; Mitsiades CS; Kotoula V; Tseleni-Balafouta S; Ashkenazi A; Koutras DA; Mitsiades N
Am J Pathol; 2002 Aug; 161(2):643-54. PubMed ID: 12163389
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative syndromes.
Bosque A; Aguiló JI; del Rey M; Paz-Artal E; Allende LM; Naval J; Anel A
J Leukoc Biol; 2008 Aug; 84(2):488-98. PubMed ID: 18483205
[TBL] [Abstract][Full Text] [Related]
18. TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality.
Corazza N; Jakob S; Schaer C; Frese S; Keogh A; Stroka D; Kassahn D; Torgler R; Mueller C; Schneider P; Brunner T
J Clin Invest; 2006 Sep; 116(9):2493-9. PubMed ID: 16955144
[TBL] [Abstract][Full Text] [Related]
19. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity.
Mirandola P; Ponti C; Gobbi G; Sponzilli I; Vaccarezza M; Cocco L; Zauli G; Secchiero P; Manzoli FA; Vitale M
Blood; 2004 Oct; 104(8):2418-24. PubMed ID: 15205263
[TBL] [Abstract][Full Text] [Related]
20. Responding naive T cells differ in their sensitivity to Fas engagement: early death of many T cells is compensated by costimulation of surviving T cells.
Maksimow M; Santanen M; Jalkanen S; Hänninen A
Blood; 2003 May; 101(10):4022-8. PubMed ID: 12531803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
